Key result
Melatonin cuts VF maintenance ~80% in failing hearts, but hypothermia negates the benefit.
Why the study?
The electrophysiological mechanisms of melatonin's antiarrhythmic effects and the impact of therapeutic hypothermia in acute ischemia-reperfusion injury remain largely unknown.
Does oral melatonin pretreatment prevent ischemia-reperfusion injury-induced arrhythmias in acute IR-injured failing and normal rabbit hearts undergoing therapeutic hypothermia?
Does oral melatonin pretreatment prevent ischemia-reperfusion injury-induced arrhythmias in acute IR-injured failing and normal rabbit hearts undergoing therapeutic hypothermia?
Absolute Event Rate: 0.4% vs 2%
p-value: p=<0.001
Melatonin pretreatment reduces ischemia-reperfusion-induced ventricular arrhythmias by modulating calcium handling and conduction, but superimposed therapeutic hypothermia paradoxically counteracts these antiarrhythmic benefits.
Melatonin offers no benefit with therapeutic hypothermia in this model; hypothesis-generating for arrhythmia prevention in failing hearts.
The electrophysiological mechanisms underlying melatonin’s actions and the electrophysiological consequences of superimposed therapeutic hypothermia (TH) in preventing cardiac ischemia-reperfusion (IR) injury-induced arrhythmias remain largely unknown. This study aimed to unveil these issues using acute IR-injured hearts. Rabbits were divided into heart failure (HF), HF+melatonin, control, and control+melatonin groups. HF was induced by rapid right ventricular pacing. Melatonin was administered orally (10 mg/kg/day) for four weeks, and IR was created by 60-min coronary artery ligation and 30-min reperfusion. The hearts were then excised and Langendorff-perfused for optical mapping studies at normothermia, followed by TH. Melatonin significantly reduced ventricular fibrillation (VF) maintenance. In failing hearts, melatonin reduced the spatially discordant alternans (SDA) inducibility mainly by modulating intracellular Ca2+ dynamics via upregulation of sarcoplasmic reticulum Ca2+-ATPase (SERCA2a) and calsequestrin 2 and attenuating the downregulation of phosphorylated phospholamban protein expression. In control hearts, melatonin improved conduction slowing and reduced dispersion of action potential duration (APDdispersion) by upregulating phosphorylated connexin 43, attenuating the downregulation of SERCA2a and phosphorylated phospholamban and attenuating the upregulation of phosphorylated Ca2+/calmodulin-dependent protein kinase II. TH significantly retarded intracellular Ca2+ decay slowed conduction, and increased APDdispersion, thereby facilitating SDA induction, which counteracted the beneficial effects of melatonin in reducing VF maintenance.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2025) studied Acute ischemia-reperfusion injury and heart failure (n=40). Melatonin vs. No melatonin (control) was evaluated on Ventricular fibrillation (VF) maintenance severity score in failing hearts at baseline (p=<0.001). Melatonin pretreatment significantly reduced ventricular fibrillation maintenance severity in failing rabbit hearts with acute ischemia-reperfusion injury at normothermia, but this protective effect was counteracted by therapeutic hypothermia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: